In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole;Susceptibilidad in vitro a hexadecilfosfocolina (miltefosina), nifurtimox y benznidazole de cepas de Trypanosoma cruzi aisladas en Santander, Colombia

Biomedica

Volumn 29, Issue 3, 2009, Pages 448-455

  Luna, Katherine Paola ^a   Hernández, Indira Paola ^a   Rueda, César Mauricio ^a   Zorro, María Magdalena ^a   Croft, Simon L ^b   Escobar, Patricia ^a  

^a UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Benznidazole; Chagas disease; Colombia; Drug therapy; Miltefosine; Nifurtimox; Trypanosoma cruzi

Indexed keywords

TRYPANOSOMA CRUZI;

ANTIPROTOZOAL AGENT; BENZNIDAZOLE; DRUG DERIVATIVE; MILTEFOSINE; NIFURTIMOX; NITROIMIDAZOLE DERIVATIVE; PHOSPHORYLCHOLINE;

ARTICLE; COLOMBIA; DRUG EFFECT; DRUG SENSITIVITY; TRYPANOSOMA CRUZI;

ANTIPROTOZOAL AGENTS; COLOMBIA; NIFURTIMOX; NITROIMIDAZOLES; PARASITIC SENSITIVITY TESTS; PHOSPHORYLCHOLINE; TRYPANOSOMA CRUZI;

EID: 77954212702     PISSN: 01204157     EISSN: None     Source Type: Journal    
DOI: 10.7705/biomedica.v29i3.15     Document Type: Article

References (39)

1. World Health Organization. Tropical disease research, progress 2003-2004: 17th Programme Report of the UNICEF/UNDP/World Bank/WHO. Special Programme for Research and Training in Tropical Diseases. Report No. 17. Geneva: WHO; 2005.
2. Brisse S, Barnabe C, Tibayrenc M. Identification of six Trypanosoma cruzi phylogenetic lineages by random amplified polymorphic DNA and multilocus enzyme electrophoresis. Int J Parasitol. 2000;30:35-44.
3. Saravia NG, Holguin AF, Cibulskis RE, D'Alessandro A. Divergent isoenzyme profiles of sylvatic and domiciliary Trypanosoma cruzi in the eastern plains, piedmont, and highlands of Colombia. Am J Trop Med Hyg. 1987;36:59-69.
4. Ruiz-García M, Montilla M, Nicholls SO, Angarita L, Álvarez D. Genetic relationships and spatial genetic structure among clonal stocks of Trypanosoma cruzi in Colombia. Heredity. 2000;85:318-27.
5. Cuervo P, Cupolillo E, Segura I, Saravia N, Fernandes O. Genetic diversity of Colombian sylvatic Trypanosoma cruzi isolates revealed by the ribosomal DNA. Mem Inst Oswaldo Cruz. 2002;97:877-80.
6. Montilla MM, Guhl F, Jaramillo C, Nicholls S, Barnabe C, Bosseno MF, et al. Isoenzyme clustering of Trypanosomatidae Colombian populations. Am J Trop Med Hyg. 2002;66:394-400.
7. Salazar A, Schijman AG, Triana-Chávez O. High variability of Colombian Trypanosoma cruzi lineage I stocks as revealed by low-stringency single primer-PCR minicircle signatures. Acta Trop. 2006;100:110-8.
8. Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz. 2003;98:577-91.
9. Gutiérrez R, Angulo VM, Tarazona Z, Britto C, Fernandes O. Comparison of four serological tests for the diagnosis of Chagas disease in a Colombian endemic area. Parasitology. 2004;129:439-44.
10. Sosa S, Segura E. Tratamiento de la infección por Trypanosoma cruzi en fase indeterminada. Experiencia y normatización actual en la Argentina. Medicina. 1999;59(Suppl.2):166-70.
11. Lauria-Pires L, Braga MS, Vexenat AC, Nitz N, Simoes-Barbosa A, Tinoco DL, et al. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg. 2000;63:111-8.
12. Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. 2003;19:495-501.
13. Jannin J, Villa L. An overview of Chagas disease treatment. Mem Inst Oswaldo Cruz. 2007;102(Suppl.1):95-7.
14. Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis. 2007;196:591-8.
15. Soto J, Soto P. Miltefosina oral para el tratamiento de la leishmaniasis. Biomédica. 2006;26(Suppl.1):207-17.
16. Croft SL, Seifert K, Duchene M. Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol. 2003;126:165-72.
17. Saraiva VB, Gibaldi D, Previato JO, Mendonca-Previato L, Bozza MT, Freire-De-Lima CG, et al. Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi. Antimicrob Agents Chemother. 2002;46:3472-7.
18. Lira R, Contreras LM, Rita RM, Urbina JA. Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J Antimicrob Chemother. 2001;47:537-46.
19. Santa-Rita RM, Santos H, Meirelles MN, de Castro SL. Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop. 2000;75:219-28.
20. Santa-Rita RM, Lira R, Barbosa HS, Urbina JA, de Castro SL. Anti-proliferative synergy of lysophospholipid analogues and ketoconazole against Trypanosoma cruzi (Kinetoplastida: Trypanosomatidae): cellular and ultrastructural analysis. J Antimicrob Chemother. 2005;55:780-4.
21. Andrade SG, Andrade V, Brodskyn C, Magalhaes JB, Netto MB. Immunological response of Swiss mice to infection with three different strains of Trypanosoma cruzi. Ann Trop Med Parasitol. 1985;79:397-407.
22. Filardi LS, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg. 1987;81:755-9.
23. Revollo S, Oury B, Laurent JP, Barnabe C, Quesney V, Carriere V, et al. Trypanosoma cruzi: impact of clonal evolution of the parasite on its biological and medical properties. Exp Parasitol. 1998;89:30-9.
24. Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother. 1996;38:1041-7.
25. Klenner T, Beckers T, Nooter K, Holtmann H. Influence of hexadecylphosphocholine (miltefosine) on cytokine synthesis and biological responses. Adv Exp Med Biol. 1996;416:181-7.
26. Escobar P, Matu S, Marques C, Croft SL. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and ampho-tericin B. Acta Trop. 2002;81:151-7.
27. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Díaz A, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis. 2004;38:1266-72.
28. Escobar P, Yardley V, Croft SL. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother. 2001;45:1872-5.
29. Murray HW, Delph-Etienne S. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J Infect Dis. 2000;181:795-9.
30. Maya JD, Repetto Y, Agosin M, Ojeda JM, Téllez R, Gaule C, et al. Effects of nifurtimox and benznidazole upon glutathione and trypanothione content in epimastigote, trypomastigote and amastigote forms of Trypanosoma cruzi. Mol Biochem Parasitol. 1997;86:101-6.
31. de Castro SL. The challenge of Chagas' disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi. Acta Trop. 1993;53:83-98.
32. Andrade SG, Rassi A, Magalhaes JB, Ferriolli Filho F, Luquetti AO. Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains. Trans R Soc Trop Med Hyg. 1992;86:624-6.
33. Toledo MJ, Guilherme AL, da Silva JC, de Gasperi MV, Mendes AP, Gomes ML, et al. Trypanosoma cruzi: chemotherapy with benznidazole in mice inoculated with strains from Parana state and from different endemic areas of Brazil. Rev Inst Med Trop Sao Paulo. 1997;39:283-90.
34. Murta SM, Gazzinelli RT, Brener Z, Romanha AJ. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol Biochem Parasitol. 1998;93:203-14.
35. Laurent JP, Barnabe C, Quesney V, Noel S, Tibayrenc M. Impact of clonal evolution on the biological diversity of Trypanosoma cruzi. Parasitology. 1997;114:213-8.
36. de Lana M, da Silveira A, Barnabe C, Quesney V, Noel S, Tibayrenc M. Trypanosoma cruzi: compared vectorial transmissibility of three major clonal genotypes by Triatoma infestans. Exp Parasitol. 1998;90:20-5.
37. Toledo MJ, de Lana M, Carneiro CM, Bahia MT, Machado-Coelho GL, Veloso VM, et al. Impact of Trypanosoma cruzi clonal evolution on its biological properties in mice. Exp Parasitol. 2002;100:161-72.
38. Toledo MJ, Bahia MT, Carneiro CM, Martins-Filho OA, Tibayrenc M, Barnabe C, et al. Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes. Antimicrob Agents Chemother. 2003;47:223-30.
39. Villarreal D, Barnabe C, Sereno D, Tibayrenc M. Lack of correlation between in vitro susceptibility to benznidazole and phylogenetic diversity of Trypanosoma cruzi, the agent of Chagas disease. Exp Parasitol. 2004;108:24-31.